Yes, insurance covers TMS therapy for most patients with major depressive disorder who meet medical necessity criteria, and coverage has expanded significantly since TMS received FDA approval in 2008. Most major commercial insurance plans including Aetna, Cigna, Blue Cross Blue Shield, UnitedHealthcare, and Humana now cover TMS for treatment-resistant depression, and Medicare covers it for patients with severe major depressive disorder who meet eligibility criteria. Coverage typically requires a diagnosis of major depressive disorder, documentation of treatment resistance including prior antidepressant trials, and prior authorization before treatment begins. Specific requirements vary: Aetna requires two failed antidepressants plus one augmenting agent; Blue Cross Blue Shield and United Healthcare require two medications from different classes. Medicare has relaxed its requirements and now typically requires documentation of one failed antidepressant rather than the four previously required. Moment of Clarity's admissions team provides free insurance verification and manages prior authorization on behalf of patients. Call 949-625-0564.

Getting TMS covered by insurance requires comprehensive documentation of medical necessity that typically includes a formal diagnosis of major depressive disorder confirmed by a licensed psychiatrist or physician, documentation of prior antidepressant medication trials including the specific medications used, doses, duration, and patient response to each, and a clinical statement confirming that the patient meets the insurer's definition of treatment-resistant depression. Some insurers also require documentation of prior psychotherapy participation, and certain plans specify that the antidepressant trials must have been from different pharmacological classes. The treating psychiatrist's letter supporting TMS as the most appropriate next intervention, including the clinical reasoning, is often required. Medical records confirming the prior treatment history, including prescribing records or pharmacy records, may also be requested. Moment of Clarity's admissions team assists in gathering all required documentation, coordinates with referring providers to obtain records, and submits the complete prior authorization package on behalf of patients to minimize the administrative burden on the patient and their physicians. Call 949-625-0564.

Yes, Medicare covers TMS therapy under Medicare Part B as an outpatient medical service for patients struggling with severe major depressive disorder. Medicare has relaxed its historical requirement of four failed antidepressant trials, and most current Medicare policies require documentation of only one failed antidepressant medication trial at an adequate dose and duration before TMS is covered, making it significantly more accessible to Medicare-covered patients than previously. A psychiatrist must evaluate the patient in person and review their medical history before ordering TMS, and prior authorization processes vary by Medicare Advantage plan versus traditional fee-for-service Medicare. Medicare-covered TMS is particularly relevant for older adults with treatment-resistant depression, who may be more sensitive to antidepressant side effects and for whom TMS's non-pharmacological mechanism is a clinically meaningful advantage. The Moment of Clarity admissions team verifies Medicare TMS coverage for patients and manages the authorization process. Call 949-625-0564.

Tricare covers TMS as part of its basic benefit package for eligible beneficiaries including active-duty service members, military retirees, eligible family members, and National Guard and Reserve members who meet specific clinical criteria. Tricare began covering TMS in 2016 for major depressive disorder, and prior authorization is required before treatment begins. Active-duty members under current Tricare TMS requirements typically need documentation of failing at least four different antidepressant medications without success, though requirements may vary by plan and have evolved over time, and the admissions team can confirm current criteria for your specific plan. Tricare does not currently cover TMS for PTSD, anxiety disorders, or other conditions as standalone indications, though TMS for treatment-resistant depression co-occurring with PTSD may be covered under the depression indication. Moment of Clarity accepts Tricare and Tricare West and manages the prior authorization process on behalf of military-affiliated patients. Call 949-625-0564 to verify your Tricare TMS coverage.

If insurance denies TMS coverage, the denial is not the final word, and a well-structured appeal supported by strong clinical documentation succeeds in a meaningful proportion of cases. Most denials are based on administrative issues such as incomplete documentation, insufficient evidence of treatment resistance, or procedural errors in the prior authorization submission, and these can often be resolved by submitting additional documentation or requesting a peer-to-peer review between the treating clinician and the insurer's medical reviewer. A peer-to-peer review allows the Moment of Clarity psychiatrist to directly discuss the clinical case with the insurer's physician reviewer, which is often the most effective way to overturn an initial denial. If an internal appeal is denied, patients also have the right to request an independent external review of the insurer's decision by a third-party reviewer. Moment of Clarity's admissions team has experience managing TMS insurance appeals and supports patients through the entire process at no cost. Call 949-625-0564 to discuss your specific coverage situation.

Coverage for TMS maintenance and retreatment sessions is more variable and complex than coverage for the initial treatment course, and the specific rules differ significantly between insurers. For the initial treatment course, most insurers apply the same criteria consistently: documented TRD diagnosis plus prior antidepressant failures plus prior authorization. For retreatment when depression recurs after a successful initial course, some insurers cover additional TMS courses with new prior authorization, while others have specific intervals that must pass before retreatment is covered, and others treat retreatment the same as the initial course. Maintenance TMS, meaning occasional single or clustered sessions to prevent relapse in a stable patient, is covered by fewer plans and with more restrictive criteria than initial treatment courses. The Moment of Clarity admissions team can verify your specific plan's retreatment and maintenance TMS coverage before any additional sessions are initiated, ensuring you understand the coverage situation before committing to additional treatment. Call 949-625-0564.

Yes, Moment of Clarity's admissions team fully manages the TMS prior authorization process on behalf of patients, handling all communication with the insurer from initial submission through approval, and supporting appeals if initial authorization is denied. The team gathers and submits the required clinical documentation including diagnosis confirmation, treatment history, and physician statements, coordinates with referring providers for supporting records when needed, and follows up with the insurer throughout the review period. Patients are kept informed of the authorization status and timeline at each step, so there are no surprises about timing or requirements. The goal is to ensure that administrative complexity does not delay access to needed clinical care for any patient. Free insurance verification is the first step and can be completed with a single call. There is no cost to patients for the authorization management service. Call 949-625-0564 to begin.

The prior authorization process for TMS insurance coverage begins with Moment of Clarity's admissions team submitting a prior authorization request to your insurer that includes clinical documentation establishing medical necessity, typically consisting of a diagnosis confirmation, a summary of prior antidepressant treatment failures, a statement from the treating psychiatrist supporting TMS as the most appropriate next intervention, and any additional documentation specific to your insurer's criteria. The insurer's utilization management team reviews the submission and may request additional information or documentation before rendering a decision. Response timelines vary by insurer, ranging from a few business days to a few weeks for most standard TMS authorizations. If additional information is requested, the Moment of Clarity team responds promptly to avoid delays. Prior authorization approval confirms that the insurer agrees the treatment is medically necessary and that covered benefits will apply, though the specific cost-sharing you pay depends on your plan's deductible and coinsurance structure. Call 949-625-0564 to begin the authorization process.

The number of prior antidepressant trials required before insurance covers TMS varies by insurer and has generally been decreasing as TMS coverage has expanded. Most major commercial insurers including Blue Cross Blue Shield and UnitedHealthcare currently require two failed antidepressant trials from different medication classes. Aetna requires two failed antidepressants plus one augmenting agent trial. Medicare has recently relaxed its requirements and currently requires documentation of only one failed antidepressant medication at a therapeutic dose for adequate duration. Tricare for active-duty members has historically required documentation of up to four failed antidepressant trials, though requirements vary by plan and may have evolved, and the Moment of Clarity admissions team can confirm current Tricare TMS requirements for your specific plan. Some insurers additionally require documentation of prior psychotherapy participation alongside medication trials. These requirements reflect the insurer's application of treatment-resistance criteria before authorizing TMS as an appropriate next intervention. The more failed antidepressant trials are documented, the stronger the insurance case for TMS, and the admissions team assists in compiling this documentation comprehensively. Call 949-625-0564 to discuss your specific prior treatment history and coverage situation.

TMS coverage for patients with co-occurring anxiety and depression is supported by the FDA's 2021 approval of TMS specifically for anxious depression, formally defined as major depressive disorder with anxious distress, which reflects clinical evidence that TMS effectively addresses both conditions simultaneously. This specific FDA indication for anxious depression strengthens insurance coverage for patients with co-occurring presentations compared to the treatment-resistant depression indication alone, as it documents clinical validation for precisely this patient population. Most commercial insurers that cover TMS for depression will cover it for anxious depression when documentation establishes the diagnosis meets the anxious depression criteria. Patients with co-occurring anxiety and depression who have not responded to medications are among the strongest TMS candidates both clinically and from an insurance coverage perspective. The Moment of Clarity admissions team ensures that the diagnosis documentation submitted for prior authorization accurately reflects the anxious depression presentation when applicable, maximizing coverage support. Call 949-625-0564 to discuss your specific co-occurring presentation and coverage situation.